The cost-effectiveness of universal asymptomatic preoperative SARS-CoV-2 PCR screening: a cost-utility analysis.

Shunsuke Uno Rei Goto Kimiko Honda Sho Uchida Yoshifumi Uwamino Ho Namkoong Ayumi Yoshifuji Kei MikitaYaoko TakanoMorio MatsumotoYuko KitagawaNaoki Hasegawa

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Asymptomatic preoperative universal SARS-CoV-2 PCR screening is not cost-effective in the base case analysis. The cost-effectiveness mainly depends on the test-positive rate, the frequency of postoperative pulmonary complications, and the screening costs; however, no matter how high the test-positive rate, the cost-effectiveness is poor if the probability of developing postoperative pulmonary complications among patients positive for SARS-CoV-2 is sufficiently reduced.

Keyphrases

sars cov
patients undergoing
respiratory syndrome coronavirus
pulmonary hypertension
risk factors
coronavirus disease